The Impact We’ve Made

Multiple Sclerosis NZ has a proud history of advocacy that has led to meaningful improvements in the lives of people with MS. From advocating for the availability of high-efficacy disease modifying therapies (DMTs), expanding access aligning with international guidelines, we’ve led significant change which is now seeing over 3000 people with MS receive funded access to treatments, earlier access than ever before meaning people are living well.

Learn more about the milestones we’ve reached, the voices that powered them, and how our efforts continue to shape a better future for the MS community. Much of our work is a testament to what strong, united advocacy can achieve.

Ensuring New Zealanders have access to high-efficacy treatments

Since 2014 Pharmac has approved the funding of 5 disease modifying therapies for relapsing forms of MS. Almost 3000 New Zealanders are now accessing funded treatments improving their long-term health outcomes.

The world of MS treatments is continually advancing. Multiple Sclerosis NZ is regularly horizon scanning the latest advances in MS treatments and advocates for evidence-based disease modifying therapies (DMTs). Ensuring access to the full range of DMTs, enables clinicians and patients to adopt the most appropriate treatment strategy that optimises effectiveness and safety for each individual.

Ocrelizumab, the first treatment funded for Primary Progressive MS

In October 2023, after 6 years of advocacy, Pharmac approved funding of Ocrelizumab for Primary Progressive MS which affects 10-15% of those diagnosed with MS. A significant milestone in the management of the most progressive form of MS, the move emphasised the importance of preserving long-term brain health. 

While Ocrelizumab is available in 26 other countries, New Zealand is the first in the Asia-Pacific region and one of only four English speaking countries at the time with funded access alongside the UK, Ireland and Canada. This result serves as a beacon of hope that many individuals have been desperately seeking in their treatment journey.

Widening access for MS treatments for Relapsing MS

Beginning in 2014 we called on Pharmac to widen the entry criteria for MS disease modifying therapies (DMTs) which was unnecessarily restrictive, and lacking evidence. In March 2021, the first step towards success was achieved with extensions to the stopping criteria, keeping patients on treatment for longer than ever before. In June 2022, recommendations to the starting criteria were approved ensuring patients no longer had to wait for a second episode of symptoms, attack or relapse, before they can begin treatment.

This hard-fought advocacy took 7 years of work by Multiple Sclerosis NZ. A huge step forward in the treatment of MS in New Zealand prioritising the importance of early intervention being vital for preserving long-term brain health, reducing the likelihood of premature disease progression or disability.

Advocating to improve funding inequities for people with disabilities

Changes to disability funding in 2024 caused significant upset and distress to many. We worked with our alliance partners to ensure the voices of the disability and caring communities were heard, meeting with MPs, hosting hui’s to consult with our members, people with MS and their carers to highlight the devastating impacts the changes brought for many. We made submissions for change highlighting the issues we heard in our community. In September 2025 it was announced a return to flexible funding.

Calling out inequities in MS treatment access

In May 2024, Multiple Sclerosis NZ raised how critical workforce shortages are impacting patients with Primary Progressive MS (PPMS) access to time sensitive disease modifying therapies. A business case prepared by clinical specialists had been under review for five months asking for more resourcing to meet patient needs and ensure safe levels of working for staff and patients.

Within 48 hours, we were advised Canterbury patients with PPMS no longer be denied access.

aHSCT now available in NZ

Autologous haematopoetic stem cell transplant (aHSCT) has captured the interest of patients and clinicians worldwide. Numerous New Zealanders have travelled overseas undergoing intensive treatment in foreign countries, away from loved ones and at significant financial cost.

Our extensive advocacy campaign began in 2017, bringing international aHSCT specialist, the late Professor Ricardo Saccardi to Aotearoa to speak with patients and leading clinicians. Our efforts also included engagements with the Ministry of Health, working alongside patient advocates to secure a 10,000 strong petition and presentation to the Health Select Committee.

Inspired by the increasing evidence from overseas a Committee of NZ Haematologists and Neurologists developed a New Zealand access criteria. Aotearoa has now begun successfully treating eligible patients with aHSCT.

Ensuring New Zealanders have access to high-efficacy treatments

Since 2014 Pharmac has approved the funding of 5 disease modifying therapies for relapsing forms of MS. Almost 3000 New Zealanders are now accessing funded treatments improving their long-term health outcomes.

Ocrelizumab, the first treatment funded for Primary Progressive MS

In October 2023, after 6 years of advocacy, Pharmac approved funding of Ocrelizumab for Primary Progressive MS which affects 10-15% of those diagnosed with MS.

A significant milestone in the management of Primary Progressive MS, the move emphasised the importance of preserving long-term brain health. While Ocrelizumab is available in 26 other countries, New Zealand is the first in the Asia-Pacific region and one of only four English speaking countries at the time with funded access alongside the UK, Ireland and Canada. This result serves as a beacon of hope that many individuals have been desperately seeking in their treatment journey.

Widening access for MS treatments for Relapsing MS

Beginning in 2014 we called on Pharmac to widen the entry criteria for MS disease modifying therapies (DMTs) which was unnecessarily restrictive, and lacking evidence.

In March 2021, the first step towards success was achieved with extensions to the stopping criteria, keeping patients on treatment for longer than ever before. In June 2022, recommendations to the starting criteria were approved ensuring patients no longer had to wait for a second episode of symptoms, attack or relapse, before they can begin treatment.

This hard-fought advocacy took 7 years of work by Multiple Sclerosis NZ. A huge step forward in the treatment of MS in New Zealand prioritising the importance of early intervention being vital for preserving long-term brain health, reducing the likelihood of premature disease progression or disability.

Calling out inequities in MS treatment access

In May 2024, Multiple Sclerosis NZ raised how critical workforce shortages are impacting patients with Primary Progressive MS (PPMS) access to time sensitive disease modifying therapies.

A business case prepared by clinical specialists had been under review for five months asking for more resourcing to meet patient needs and ensure safe levels of working for staff and patients. Within 48 hours, we were advised Canterbury patients with PPMS no longer be denied access.

Advocating to improve funding inequities for people with disabilities

Changes to disability funding in 2024 caused significant upset and distress to many.

We worked with our alliance partners to ensure the voices of the disability and caring communities were heard, meeting with MPs, hosting hui’s to consult with our members, people with MS and their carers to highlight the devastating impacts the changes brought for many. We made submissions for change highlighting the issues we heard in our community. In September 2025 it was announced a return to flexible funding.

aHSCT now available in NZ

Autologous haematopoetic stem cell transplant (aHSCT) has captured the interest of patients and clinicians worldwide.

Numerous New Zealanders have travelled overseas undergoing intensive treatment in foreign countries, away from loved ones and at significant financial cost.

Our extensive advocacy campaign began in 2017, bringing international aHSCT specialist, the late Professor Ricardo Saccardi to Aotearoa to speak with patients and leading clinicians. Our efforts also included engagements with the Ministry of Health, working alongside patient advocates to secure a 10,000 strong petition and presentation to the Health Select Committee.

Inspired by the increasing evidence from overseas a Committee of NZ Haematologists and Neurologists developed a New Zealand access criteria. Aotearoa has now begun successfully treating eligible patients with aHSCT.

Empowering Lives, Driving Change

At MSNZ, we’re dedicated to making a measurable difference in the lives of people living with Multiple Sclerosis, their families, and carers. This section highlights the tangible outcomes of our advocacy, education, and support initiatives across Aotearoa. 

From advancing access to treatments to strengthening regional services and promoting brain health strategies, our work empowers individuals to live well with MS. Explore the stories, statistics, and milestones that reflect the positive change we’re making together with our community and partners.

Creating Real Change for People with MS

Our impact is demonstrated through the progress we’ve made and the direction we’re heading. MSNZ’s advocacy and community work are making a real difference in the lives of those living with MS.

Current Advocacy Priorities

We are actively advocating for greater access to treatments, faster diagnosis, and improved support services across New Zealand. Our work focuses on removing systemic barriers and ensuring people with MS receive the care and respect they deserve.

Explore our latest campaigns, policy submissions, and collaborations with government, researchers, and community groups. Stay informed about how we’re driving progress and where your voice can make an impact.

Past Advocacy Achievements

MSNZ has a proud history of advocacy that has led to meaningful improvements in the lives of people with MS. From expanding access to funded medications like Ocrevus and Lemtrada, to shaping national treatment guidelines, we’ve led significant change.

This section showcases the milestones we’ve reached, the voices that powered them, and how our efforts continue to shape a better future for the MS community. It’s a testament to what strong, united advocacy can achieve.

Publications & Reports

MSNZ is committed to transparency, accountability, and sharing knowledge with the MS community, health professionals, and the public. Our publications and reports provide insight into our achievements, challenges, and the impact of our work.

Annual Reports

Annual Reports offer a comprehensive overview of MSNZ’s activities, advocacy, and financial performance over the past year. They highlight our achievements, the challenges faced by the MS community, and our ongoing commitment to improving the lives of people affected by MS.
  • What’s included:
    • Overview of the year’s highlights and challenges
    • Advocacy updates and achievements
    • Future directions and priorities
    • Stories from the MS community
    • Auditor’s report

Annual Audited Accounts

Annual Audited Accounts provide a detailed and independent review of MSNZ’s financial position and performance. These documents are prepared in accordance with New Zealand accounting standards and are audited by an independent auditor.

  • What’s included:
    • Statement of financial performance
    • Statement of financial position
    • Statement of cash flows
    • Notes to the accounts and summary of significant accounting policies
    • Auditor’s report

Strategic Plan

Strategic Plan outlines MSNZ’s vision, mission, and strategic priorities for the coming years. It guides our work and ensures we remain focused on delivering the best possible outcomes for people affected by MS.
  • What’s included:
    • Vision and mission statements
    • Key strategic priorities and goals
    • Focus areas for advocacy, support, and community engagement
    • Measures for success and impact

Additional Publications

MSNZ also produces a range of other reports, information sheets, and resources to support people living with MS, their families, and health professionals. These include:

  • Living Well with MS Information Pack
  • Knowledge is Power (KIP) Publication (an at-home educational series for people newly diagnosed with MS)
  • MSNZ Facts about MS – Leaflet
  • MS Diagnosis Card – Wallet Card
  • MS Information Posters (for healthcare providers and community groups)

You can access these and other resources on the MSNZ Resources page.

Our publications and reports are freely available to download and share, supporting transparency, education, and advocacy for the MS community in New Zealand.

Advocacy

MS Brain Health Team Award

In 2023 Multiple Sclerosis NZ was awarded the internationally acclaimed MS Brain Health Team Award for our relentless advocacy to widen access criteria to disease modifying therapies. This is an award we were honoured to receive and is a testament to the years of hard-fought advocacy, commitment and support by all those involved.

The outcomes and award were made possible not only due to the team at MSNZ, but also health professionals and MS experts from NZ and overseas who shared their knowledge and expertise, our volunteers and donors who helped to maintain momentum and of course the MS community who shared their stories and lived experiences.